These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31617004)

  • 1. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
    Crombag MBS; Koolen SLW; Wijngaard S; Joerger M; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
    Pharm Res; 2019 Oct; 36(12):163. PubMed ID: 31617004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
    Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
    Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.
    Crombag MBS; de Vries Schultink AHM; Koolen SLW; Wijngaard S; Joerger M; Schellens JHM; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
    Pharm Res; 2019 Jan; 36(2):33. PubMed ID: 30617624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
    Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
    Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
    Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
    Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
    J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.
    Mendes MS; Hatley O; Gill KL; Yeo KR; Ke AB
    Eur J Pharm Sci; 2020 Jul; 150():105355. PubMed ID: 32438273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
    Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.
    Henrich A; Joerger M; Kraff S; Jaehde U; Huisinga W; Kloft C; Parra-Guillen ZP
    J Pharmacol Exp Ther; 2017 Aug; 362(2):347-358. PubMed ID: 28600397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
    Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.
    Ait-Oudhia S; Straubinger RM; Mager DE
    Pharm Res; 2012 Oct; 29(10):2833-44. PubMed ID: 22588463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
    Ishikawa M; Kawai M; Maeda T; Kagawa Y
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):399-411. PubMed ID: 29299638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.
    Fetterly GJ; Tamburlin JM; Straubinger RM
    Biopharm Drug Dispos; 2001 Sep; 22(6):251-61. PubMed ID: 11754041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
    Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
    Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
    Sissung TM; Mross K; Steinberg SM; Behringer D; Figg WD; Sparreboom A; Mielke S
    Eur J Cancer; 2006 Nov; 42(17):2893-6. PubMed ID: 16950614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.